

HPMS E-Mail

Date: October 9, 2024

Subject: Announcement of the Medicare \$2 Drug List Model Request for Information

Today, the CMS Innovation Center released a Medicare \$2 Drug List Model Request for Information (RFI), accompanied with a sample \$2 Drug List, to support continued development of Medicare \$2 Drug List Model and obtain input from a broad range of interested parties. The RFI and a sample \$2 Drug List can be found on the [CMS Model Webpage](#). The RFI is open for comment through December 9th and we encourage Part D Sponsors to review and share input through the [online survey](#).

The Medicare \$2 Drug List Model was one of the models selected by the Secretary to be tested by the CMS Innovation Center (in response to [President Biden's Executive Order on Lowering Prescription Drug Costs for Americans](#)) and proposes to test whether a simplified approach to offering low-cost, clinically important generic drugs can improve medication adherence, lead to better health outcomes, and improve satisfaction with the Part D prescription drug benefit among people with Medicare and prescribers.